Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Manley

Showing results (371-380 of 378) with videos related to

Pageof 38
Sort By:
You have reached the last page of results.This site can display upto 378 results.
Genome Biology|March 3, 2017
Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signaturesYasin Şenbabaoğlu, Ron S Gejman, Andrew G Winer, et al.
Trials|January 8, 2026
Avoiding routine gastric residual volume measurement in neonatal critical care (the neoGASTRIC trial): study protocol for a multi-centre, unblinded, randomised, controlled trialElizabeth Nuthall, Amy Rodriquez, Iza Andrzejewksa, et al.
JAMA|November 11, 2024
Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical TrialBrett J Manley, C Omar F Kamlin, Susan M Donath, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
Discovery of a novel and potent class of FabI-directed antibacterial agentsDavid J Payne, William H Miller, Valerie Berry, et al.
Journal of Medicinal Chemistry|January 14, 2000
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimeticW H Miller, D P Alberts, P K Bhatnagar, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
Cancer Discovery|June 27, 2022
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell CarcinomaPhillip M Rappold, Lynda Vuong, Josef Leibold, et al.
Nature Genetics|April 26, 2024
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regionsMark P Purdue, Diptavo Dutta, Mitchell J Machiela, et al.
Pageof 38

Showing results (371-380 of 378) with videos related to

Sort By:
Pageof 38
You have reached the last page of results.This site can display upto 378 results.
Genome Biology|March 3, 2017
Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signaturesYasin Şenbabaoğlu, Ron S Gejman, Andrew G Winer, et al.
Trials|January 8, 2026
Avoiding routine gastric residual volume measurement in neonatal critical care (the neoGASTRIC trial): study protocol for a multi-centre, unblinded, randomised, controlled trialElizabeth Nuthall, Amy Rodriquez, Iza Andrzejewksa, et al.
JAMA|November 11, 2024
Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical TrialBrett J Manley, C Omar F Kamlin, Susan M Donath, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
Discovery of a novel and potent class of FabI-directed antibacterial agentsDavid J Payne, William H Miller, Valerie Berry, et al.
Journal of Medicinal Chemistry|January 14, 2000
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimeticW H Miller, D P Alberts, P K Bhatnagar, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
Cancer Discovery|June 27, 2022
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell CarcinomaPhillip M Rappold, Lynda Vuong, Josef Leibold, et al.
Nature Genetics|April 26, 2024
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regionsMark P Purdue, Diptavo Dutta, Mitchell J Machiela, et al.
Pageof 38